(34.200.222.93)
Users online: 5006    [ij] [ij] [ij] 
Email id
 

Asian Journal of Research in Pharmaceutical Science
Year : 2020, Volume : 10, Issue : 2
First page : ( 100) Last page : ( 102)
Print ISSN : 2231-5640. Online ISSN : 2231-5659.
Article DOI : 10.5958/2231-5659.2020.00019.3

Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate

Kshirsager Sandip S.1,*, Dr. Shaikh Siraj N.1, Patil Narendra B.2, Patil Ketan B.2

1Department of Pharmaceutics, Ali Allana College of Pharmacy, Akkalkuwa, Maharashtra

2Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, Dist-Dhule, Maharashtra

*Corresponding Author E-mail: sandipkshirsagar53@gmail.com

Online published on 3 June, 2020.

Abstract

Cancer is leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. Breast cancer 2.09 million death in 2018. Approximately 70% of deaths from cancer occurs in low-and middle-income countries. Human epidermal growth factor receptor (HER) 2 is overexpressed in 20–25% of breast cancer and has historically been poor prognostics marker. Niratinib maleate is an anti breast cancer drug.it is crystalline form and chemically (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl) methoxy] phenyl] amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino) but-2-enamide maleate. It an oral, irreversible pan-Erb B receptor tyrosine kinase inhibitor and it can effectively inhibit the activity of Erb B1, ErbB2 tyrosine kinase.

Top

Keywords

Breast cancer, tyrosine kinase, Niratinib maleate, HER (Human epidermal growth factor receptor).

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
436,548,372 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.